Correction: Updated Public Health Impact and Cost Effectiveness of Recombinant Zoster Vaccine in Canadian Adults Aged 50 Years and Older.
Sydney GeorgeJustin CarricoKatherine A HicksDessi LoukovCheryl NgJessica ReganNikolaos GiannelosPublished in: PharmacoEconomics - open (2024)